标题
Alleviating anemia and thrombocytopenia in myelofibrosis patients
作者
关键词
-
出版物
Expert Review of Hematology
Volume 9, Issue 5, Pages 489-496
出版商
Informa UK Limited
发表日期
2016-02-20
DOI
10.1586/17474086.2016.1154452
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results
- (2015) Francisco Cervantes et al. ANNALS OF HEMATOLOGY
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
- (2015) R. S. Komrokji et al. BLOOD
- Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).
- (2015) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
- (2015) N M Kröger et al. LEUKEMIA
- Long-term results of prednisone treatment for the anemia of myelofibrosis
- (2015) Juan-Carlos Hernández-Boluda et al. LEUKEMIA & LYMPHOMA
- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
- (2014) E. Rumi et al. BLOOD
- How I treat myelofibrosis
- (2014) F. Cervantes BLOOD
- The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis
- (2014) J.-C. Hernandez-Boluda et al. HAEMATOLOGICA
- Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
- (2014) A Pardanani et al. LEUKEMIA
- Novel myelofibrosis treatment strategies: potential partners for combination therapies
- (2014) B L Stein et al. LEUKEMIA
- Clinical significance of microcytosis in patients with primary myelofibrosis
- (2014) Paolo Strati et al. LEUKEMIA RESEARCH
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis
- (2013) Aziz Nazha et al. LEUKEMIA & LYMPHOMA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
- (2013) Srdan Verstovsek et al. OncoTargets and Therapy
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
- (2012) A. Deisseroth et al. CLINICAL CANCER RESEARCH
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia
- (2012) Cristina Sanz et al. TRANSFUSION
- Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
- (2011) L. Malcovati et al. HAEMATOLOGICA
- Prognostication in Primary Myelofibrosis
- (2011) Francisco Cervantes et al. Current Hematologic Malignancy Reports
- Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
- (2010) Alejandra Martínez-Trillos et al. ANNALS OF HEMATOLOGY
- Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
- (2010) R. A. Mesa et al. BLOOD
- Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients
- (2010) P. Morel et al. BLOOD
- Bone marrow histopathology in primary myelofibrosis: Clinical and haematologic correlations and prognostic evaluation
- (2010) Arturo Pereira et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS
- (2010) C. Elena et al. HAEMATOLOGICA
- Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked
- (2010) M. A. Elliott et al. HAEMATOLOGICA
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase-2 trial of low-dose pomalidomide in myelofibrosis
- (2010) K H Begna et al. LEUKEMIA
- Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
- (2010) D Caramazza et al. LEUKEMIA
- What are RBC-transfusion-dependence and -independence?
- (2010) R.P. Gale et al. LEUKEMIA RESEARCH
- Thrombosis in primary myelofibrosis: incidence and risk factors
- (2009) T. Barbui et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
- (2009) A Bacigalupo et al. BONE MARROW TRANSPLANTATION
- Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level
- (2009) Jocelin Huang et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
- (2009) Constantine S. Tam et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
- (2009) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Risk factors for leukemic transformation in patients with primary myelofibrosis
- (2008) Jocelin Huang et al. CANCER
- Anemia and Mortality in Heart Failure Patients
- (2008) Hessel F. Groenveld et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started